Invalidity dossier
US 4713176
Plasmapheresis system and method
Current assignee: Baxter International Inc
Added 9/23/2026, 1:21:52 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US4713176A
Title: Plasmapheresis system and method
Patent number: US4713176A
Application number: US06/722,800
Inventors: Donald W. Schoendorfer and Lee E. Hansen
Original assignee: Hemascience Laboratories, Inc. (a California corporation)
Current assignee (per listing): Baxter International Inc.
Priority/filing date: 1985-04-12
Publication (grant) date: 1987-12-15
Legal status: Expired – Lifetime (anticipated expiration 2005-04-12)
Purpose (plain language): The patent concerns a plasmapheresis system and method — that is, a technique for separating plasma from whole blood outside the body. According to the supplied excerpt, the invention relates to withdrawing blood, combining it with an anticoagulant, and passing it through a membrane so that plasma (the filtrate) is extracted while cellular components are retained. Because the patent text provided here is only an excerpt, no broader statement of purpose can be made.
Scope and classification: The document is classified under A61M1/00, A61M1/36 (extra-corporeal blood circuits; "Means preventing coagulation"), and A61M1/14–A61M1/265 (membrane-based blood treatment, including rotating membranes inducing Taylor vortices). Frequently recurring terms in the text include blood, anticoagulant, membrane, plasma, filtration, and extraction. The excerpt identifies "stabilizing" as a claim term, but the claims themselves were not supplied.
Limitations of this excerpt: The supplied text does not establish the full claims, the written description's details, or the abstract's complete wording. It also does not establish any actual legal conclusion about ownership, validity, enforceability, or prior art; the assignee and status fields are expressly captioned as assumptions or unverified listings. Statements about anticoagulant chemistry (e.g., citrate) appear only as extracted keyword annotations, not as verified claim language.
Source: https://patents.google.com/patent/[US4713176](/patent/US4713176)/en
Generated 10/1/2026, 9:53:09 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 4713176. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.